BRIEF-Neurosense Therapeutics Achieves Primary Endpoint In Phase 2B ALS Study

NeuroSense Therapeutics Ltd. Warrant 2021-open end
Neurosense Therapeutics Ltd.

NeuroSense Therapeutics Ltd. Warrant 2021-open end

NRSNW

0.00

Neurosense Therapeutics Ltd.

NRSN

0.00

June 29 (Reuters) - Neurosense Therapeutics Ltd NRSN.O:

  • NEUROSENSE ACHIEVES PRIMARY ENDPOINT IN PHASE 2B ALS STUDY WITH STATISTICALLY SIGNIFICANT REDUCTION OF TDP-43, THE DEFINING PATHOLOGICAL HALLMARK OF ALS

  • NEUROSENSE THERAPEUTICS - PRIMEC SHOWS FAVORABLE SAFETY PROFILE WITH NO NEW SAFETY SIGNALS OVER 18 MONTHS

  • NEUROSENSE THERAPEUTICS - PRIMEC SHOWS SIGNIFICANT TDP-43 REDUCTION AT DAY 180 AND DAY 540 IN PHASE 2B ALS STUDY

Source text: ID:nPn6VBrgVa

Further company coverage: NRSN.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.